• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer and Clinical Oncology >Overall Survival in Stage III and IV High-Risk Head and Neck Squamous Cell Carcinoma Patients who received Adjuvant Chemotherapy and Radiation without Cisplatin
【24h】

Overall Survival in Stage III and IV High-Risk Head and Neck Squamous Cell Carcinoma Patients who received Adjuvant Chemotherapy and Radiation without Cisplatin

机译：接受辅助化学疗法和放射治疗但未使用顺铂的Ⅲ，Ⅳ期高危头颈部鳞状细胞癌患者的总体生存率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: Microscopically involved resection margins and/or extracapsular spread represent the most significant prognostic factors for poor outcome in head and neck cancer. Purpose of this study was to estimate overall survival, and assess impact of demographic and clinicopathologic variables on survival in stage III and IV high-risk patients who received chemoradiation other than Cisplatin Methods: Retrospective review Results: The final cohort of 18 eligible patients had a median age of 66 years and males were 66.66%. Median survival was 20.5 months. Patients were trichotomized into three age groups for comparison; ≤ 60 years, 61-70 years, ≥71 years . A superior overall survival was observed with advanced age (HR, 4.02; 95%CI, 1.33-12.17, p=0.016). Overall survival was significantly lower in patients with high Charlson comorbidity scores of 3-8 when compared to those with low scores of 0-2 (HR, 25.6; 95%CI, 2.78-236.7, p=0.0009). Young patients had high comorbidity scores (CCI & 2) based on the age-groups; ≤ 60 years (60%), 61-70 years (28.57%), ≥71 years (none) . Tumor stage, positive resection margins, extracapsular spread, perineural involvement, lymphovascular invasion, tumor grade, high-risk human papillomavirus, body mass index, smoking and alcohol did not affect overall survival significantly. Conclusions: Young age and severe comorbidity should be considered when treating high-risk head and neck cancer squamous cell carcinoma patients with adjuvant chemoradiation therapy other than Cisplatin due to inferior overall survival. ?
机译：目的：显微镜下所见的切除切缘和/或囊外扩散是头颈癌预后不良的最重要预后因素。这项研究的目的是评估总体生存率，并评估人口统计学和临床​​病理学变量对接受顺铂以外化学疗法治疗的III和IV期高危患者的生存率的影响。方法：回顾性审查结果：最后队列的18名符合条件的患者中位年龄为66岁，男性为66.66％。中位生存期为20.5个月。将患者分为三个年龄段进行比较。 ≤60岁，61-70岁，≥71岁。观察到高龄患者的总体生存率更高（HR，4.02; 95％CI，1.33-12.17，p = 0.016）。具有较高Charlson合并症评分3-8的患者的总体生存率显着低于具有0-2较低评分的患者（HR，25.6; 95％CI，2.78-236.7，p = 0.0009）。根据年龄段，年轻患者合并症评分较高（CCI> 2）; ≤60年（60％），61-70年（28.57％），≥71年（无）。肿瘤分期，切缘阳性，包膜外扩散，神经周围受累，淋巴血管浸润，肿瘤等级，高危型人乳头瘤病毒，体重指数，吸烟和饮酒均未显着影响总生存期。结论：由于总生存期较差，采用顺铂以外的辅助化学放疗治疗高危头颈部鳞状细胞癌患者时应考虑年轻人和严重合并症。 ？

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号